These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

768 related articles for article (PubMed ID: 23416791)

  • 61. Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes.
    Nanchen D; Gencer B; Auer R; Räber L; Stefanini GG; Klingenberg R; Schmied CM; Cornuz J; Muller O; Vogt P; Jüni P; Matter CM; Windecker S; Lüscher TF; Mach F; Rodondi N
    Eur Heart J; 2015 Sep; 36(36):2438-45. PubMed ID: 26142466
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
    Klaus G; Taylan C; Büscher R; Schmitt CP; Pape L; Oh J; Driemeyer J; Galiano M; König J; Schürfeld C; Spitthöver R; Schaefer JR; Weber LT; Heibges A; Klingel R
    Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe.
    Ruel I; Aljenedil S; Sadri I; de Varennes É; Hegele RA; Couture P; Bergeron J; Wanneh E; Baass A; Dufour R; Gaudet D; Brisson D; Brunham LR; Francis GA; Cermakova L; Brophy JM; Ryomoto A; Mancini GBJ; Genest J
    Clin Chem; 2018 Feb; 64(2):355-362. PubMed ID: 29038147
    [TBL] [Abstract][Full Text] [Related]  

  • 64. PCSK9 and LDL cholesterol: unravelling the target to design the bullet.
    Costet P; Krempf M; Cariou B
    Trends Biochem Sci; 2008 Sep; 33(9):426-34. PubMed ID: 18672372
    [TBL] [Abstract][Full Text] [Related]  

  • 65. PCSK9: a key modulator of cardiovascular health.
    Seidah NG; Awan Z; Chrétien M; Mbikay M
    Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Defining the challenges of familial hypercholesterolemia screening: introduction.
    Hopkins PN
    J Clin Lipidol; 2010; 4(5):342-5. PubMed ID: 21122675
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.
    Wiegman A; Gidding SS; Watts GF; Chapman MJ; Ginsberg HN; Cuchel M; Ose L; Averna M; Boileau C; Borén J; Bruckert E; Catapano AL; Defesche JC; Descamps OS; Hegele RA; Hovingh GK; Humphries SE; Kovanen PT; Kuivenhoven JA; Masana L; Nordestgaard BG; Pajukanta P; Parhofer KG; Raal FJ; Ray KK; Santos RD; Stalenhoef AF; Steinhagen-Thiessen E; Stroes ES; Taskinen MR; Tybjærg-Hansen A; Wiklund O;
    Eur Heart J; 2015 Sep; 36(36):2425-37. PubMed ID: 26009596
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
    Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP
    Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Use of the denaturing gradient gel electrophoresis (DGGE) method for mutational screening of patients with familial hypercholesterolaemia (FH) and Familial defective apolipoprotein B100 (FDB).
    Azian M; Hapizah MN; Khalid BA; Khalid Y; Rosli A; Jamal R
    Malays J Pathol; 2006 Jun; 28(1):7-15. PubMed ID: 17694954
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk.
    Lee S; Akioyamen LE; Aljenedil S; Rivière JB; Ruel I; Genest J
    Eur J Prev Cardiol; 2019 Aug; 26(12):1262-1270. PubMed ID: 30755017
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recent advances in the management and implementation of care for familial hypercholesterolaemia.
    Lan NSR; Bajaj A; Watts GF; Cuchel M
    Pharmacol Res; 2023 Aug; 194():106857. PubMed ID: 37460004
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Familial hypercholesterolemia: epidemiology, genetics, diagnosis, and screening].
    Sinan ÜY; Sansoy V
    Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():1-9. PubMed ID: 25693358
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Up to date lipid lowering treatment].
    Paragh G; Karádi I
    Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Familial hypercholesterolaemia workshop for leveraging point-of-care testing and personalised medicine in association with the Lipid and Atherosclerosis Society of Southern Africa.
    Marais AD; Kotze MJ; Raal FJ; Khine AA; Talmud PJ; Humphries SE
    Cardiovasc J Afr; 2019; 30(5):297-304. PubMed ID: 31746944
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Existing and emerging therapies for the treatment of familial hypercholesterolemia.
    Rosenson RS
    J Lipid Res; 2021; 62():100060. PubMed ID: 33716107
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients.
    Pisciotta L; Fasano T; Bellocchio A; Bocchi L; Sallo R; Fresa R; Colangeli I; Cantafora A; Calandra S; Bertolini S
    Atherosclerosis; 2007 Oct; 194(2):e116-22. PubMed ID: 17140581
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Generation of Human Liver Chimeric Mice with Hepatocytes from Familial Hypercholesterolemia Induced Pluripotent Stem Cells.
    Yang J; Wang Y; Zhou T; Wong LY; Tian XY; Hong X; Lai WH; Au KW; Wei R; Liu Y; Cheng LH; Liang G; Huang Z; Fan W; Zhao P; Wang X; Ibañez DP; Luo Z; Li Y; Zhong X; Chen S; Wang D; Li L; Lai L; Qin B; Bao X; Hutchins AP; Siu CW; Huang Y; Esteban MA; Tse HF
    Stem Cell Reports; 2017 Mar; 8(3):605-618. PubMed ID: 28262545
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Familial hypercholesterolemia: etiology, diagnosis and new treatment options.
    Gouni-Berthold I; Berthold HK
    Curr Pharm Des; 2014; 20(40):6220-9. PubMed ID: 24953396
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.